Lake Street lowered the firm’s price target on Avita Medical (RCEL) to $3 from $4 and keeps a Hold rating on the shares. The firm remains on the sidelines until seeing sales stabilization and reacceleration and a more permanent financial solution to the balance sheet, the analyst tells investors in a post-earnings note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCEL: